Bausch & Lomb v. Dr. Reddy’s: Prostaglandin Patent Dispute Ends in Dismissal

Case Overview

After more than two years of litigation, a high-stakes pharmaceutical patent infringement dispute between Bausch & Lomb and Dr. Reddy’s Laboratories concluded not with a courtroom verdict, but with a negotiated stipulation of dismissal. Filed on June 27, 2023, in the U.S. District Court for the District of New Jersey, Case No. 3:23-cv-03463 centered on four patents covering prostaglandin derivatives — a compound class critical to ophthalmic drug formulations. The case closed on June 30, 2025, spanning 734 days before resolution under Federal Rule of Civil Procedure 41(a)(1)(A)(ii).

For patent attorneys tracking pharmaceutical IP litigation, in-house counsel monitoring ANDA-related enforcement trends, and R&D teams navigating freedom-to-operate risks in ophthalmic drug development, this dismissal carries meaningful strategic signals. The parties’ decision to settle rather than litigate to judgment reflects broader patterns in pharma patent enforcement — where negotiated access arrangements often serve commercial interests more effectively than prolonged trial risk.

The Parties

The Patents at Issue

This landmark case involved four U.S. patents relating to **prostaglandin derivatives** — compounds widely used in ophthalmic formulations to treat conditions such as glaucoma and ocular hypertension. These are commercially significant molecules, and patent protection over their composition, synthesis, or formulation directly governs generic market entry timelines:

• • US8058467B2 (Application No. 13/025740)
• • US7273946B2 (Application No. 11/029698)
• • US7629345B2 (Application No. 12/210975)
• • US7910767B2 (Application No. 12/613985)

Legal Representation

Bausch & Lomb retained Finnegan, Henderson, Farabow, Garrett & Dunner, LLP — one of the nation’s premier patent litigation firms — alongside Gibbons PC as New Jersey local counsel. The plaintiff’s team included attorneys Bryan C. Diner, Danielle N. Craft, J. Brugh Lower, Justin James Hasford, Stephen R. Donat, and William P. Deni, Jr.

Dr. Reddy’s was represented by Stone Conroy LLC, with Rebekah R. Conroy serving as lead defense counsel.

Litigation Timeline & Procedural History

The complaint was filed on June 27, 2023, in the District of New Jersey — a jurisdiction that has become a prominent forum for Hatch-Waxman pharmaceutical patent litigation, given its concentration of pharmaceutical industry activity and judicial familiarity with ANDA disputes.

The case proceeded at the first-instance (district court) trial level over 734 days before the parties reached resolution. While detailed intermediate milestones — including claim construction hearings, Markman rulings, or summary judgment motions — are not disclosed in publicly available docket summaries, the duration is consistent with complex pharmaceutical patent matters that involve multiple asserted patents, extensive claim mapping, and technical expert preparation.

The case closed on June 30, 2025, through a voluntary stipulated dismissal executed pursuant to a settlement agreement dated June 17, 2025. Notably, the District of New Jersey retained jurisdiction to enforce the terms of the agreement — a standard but strategically important provision ensuring judicial oversight of any future compliance disputes.

The Verdict & Legal Analysis

Outcome

The case was dismissed without prejudice pursuant to a joint stipulation under Federal Rule of Civil Procedure 41(a)(1)(A)(ii). All claims, counterclaims, and affirmative defenses were dismissed, with each party bearing its own costs, disbursements, and attorneys’ fees. No damages award or injunctive relief was granted by the court, as resolution occurred through private agreement rather than judicial determination.

The dismissal was “without prejudice,” meaning Bausch & Lomb retains the theoretical right to re-assert these patent claims in a future action — a meaningful distinction that preserves enforcement optionality.

Verdict Cause Analysis

The underlying cause of action was patent infringement — most likely triggered by DRL’s filing of an Abbreviated New Drug Application (ANDA) seeking FDA approval to market a generic prostaglandin derivative product. Under the Hatch-Waxman Act framework, such a filing constitutes a statutory act of infringement, enabling branded pharmaceutical patent holders to initiate litigation within 45 days and benefit from a 30-month regulatory stay on generic approval.

Because the case resolved without a court ruling on the merits, there is no public judicial analysis of claim construction, validity challenges, or infringement findings. However, the structure of the dismissal — particularly the agreement dated June 17, 2025, and the court’s retained jurisdiction — strongly suggests the parties reached a licensing or settlement agreement governing DRL’s future market entry date, royalty obligations, or other commercial terms. This outcome pattern is standard in Hatch-Waxman litigation, where settlements frequently include authorized generic arrangements, negotiated launch dates, or royalty-bearing licenses.

Legal Significance

While this dismissal produces no binding precedent, several legally significant observations emerge:

1. Multi-patent assertion strategy: Bausch & Lomb’s use of four patents across different application families suggests an overlapping claim strategy designed to create layered enforcement barriers — a common and effective approach in pharmaceutical IP portfolios.
2. Retained jurisdiction clause: The stipulation’s provision that the New Jersey District Court “retains jurisdiction to enforce and resolve any disputes arising under the Agreement” is a critical drafting element. It eliminates the need for a new lawsuit if either party breaches settlement terms.
3. FRCP 41(a)(1)(A)(ii) mechanism: This rule requires a signed stipulation from all parties, confirming that DRL affirmatively consented to the dismissal — distinguishing this from a unilateral Bausch & Lomb withdrawal and indicating bilateral agreement on terms.

Strategic Takeaways

For Patent Holders: Multi-patent portfolio assertion in pharmaceutical cases creates settlement leverage. Overlapping prostaglandin composition, formulation, and synthesis claims — spread across different patent families — complicates a generic challenger’s invalidity and non-infringement analysis, increasing litigation cost and risk.

For Accused Infringers (Generic Manufacturers): Early evaluation of all asserted patents for IPR (inter partes review) candidacy at the USPTO can provide parallel pressure on patent holders. A strong IPR petition can shift settlement dynamics favorably for the generic challenger.

For R&D Teams: Freedom-to-operate analysis for prostaglandin derivative products must account for patent families with multiple continuation and divisional applications. The four patents asserted here — spanning applications filed across different years — illustrate how a single compound class can generate layered IP barriers.